Breaking News

Lightlake Inks Manufacturing Contract for Naloxone

July 9, 2014

Will enable commercialization on a global scale

Lightlake Therapeutics, Inc. has signed an agreement with a commercial contract manufacturer for the production of its naloxone-based opioid overdose reversal treatment. The manufacturer will provide the manufacturing capacity needed at cGMP production facilities to enable commercialization of the treatment on a global scale.

Naloxone is an injectable drug that can reverse the overdose of prescription and illicit opioids. Lightlake has been developing an intranasal delivery system that could expand its availability and use in preventing opioid overdose deaths.

"This is a significant milestone for Lightlake in forwarding our opioid overdose reversal treatment," said Dr. Roger Crystal, chief executive officer of Lightlake. "We have been diligent in selecting our partner for the contract manufacturing process to best position us to produce a high quality treatment that can meet the requirements for FDA approval. We are confident that working with this partner will help us better serve the market need for a needleless treatment and provide us with significant competitive advantages."

Related Packaging:

Related Contract Manufacturing:

Related Compliance:

blog comments powered by Disqus
  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market

  • Flexible Manufacturing Strategies

    Kristin Brooks, Contract Pharma||April 4, 2016
    Michael Lehmann of Patheon discusses solutions for pharmaceutical forecasting errors

  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.